PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Rosuvastatin calcium - Lipid modification

PAD Profile : Rosuvastatin calcium - Lipid modification

Keywords :
Statins, primary hypercholesterolaemia, mixed dyslipidaemia, familial hypercholesterolaemia, high cholesterol, raised cholesterol, lipid lowering, lipid-lowering
Brand Names Include :
Crestor

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 October 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Rosuvastatin is not a cost-effective treatment option for most patients and should be reserved for a small number of individual patients where high-intensity statin therapy is appropriate but the alternatives are not tolerated or are contraindicated.

Rosuvastatin should ONLY be considered as GREEN on the traffic light system for these individual patients.

NICE published CG 181 in July 2014 to update and replace NICE CG 67 and NICE TA 94 (statins for the prevention of cardiovascular events). This new NICE guidance does not mention rosuvastatin so the PCN sought clarification from NICE - see update following clarification from NICE below.

If statin therapy is considered appropriate the guidelines recommend using atorvastatin 20mg for primary prevention and atorvastatin 80mg for secondary prevention.

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More